Innova Captab Q2 FY27 Net Profit at ₹422 Million

Key Decisions and Financial Results

The Board of Directors of Innova Captab Limited, at its meeting held on Friday, 13th November 2026, approved the following:

Approval of the unaudited financial results (consolidated and standalone) for the quarter and half year ended 30th September 2026.
The meeting commenced at 15:04 hours (IST) and concluded at 15:42 hours (IST).

Detailed Financial Performance (Consolidated)

Income Statement (₹ million)

| Revenue from operations | 4,962.99 | 4,708.52 | 3,803.81 | 9,671.51 | 7,319.23 | 16,300.15 |

| Other income | 24.64 | 20.07 | 41.93 | 44.71 | 86.76 | 74.20 |

| Total Income | 4,987.63 | 4,728.59 | 3,845.74 | 9,716.22 | 7,405.99 | 16,374.38 |

| Total Expenses | 4,424.65 | 4,138.74 | 3,453.39 | 8,563.39 | 6,586.87 | 11,491.74 |

| Profit before tax | 562.98 | 589.85 | 392.35 | 1,152.83 | 819.12 | 4,882.64 |

| Tax expense | 138.76 | 148.59 | 95.65 | 287.35 | 212.27 | 450.81 |

| Profit for the period | 424.22 | 441.26 | 296.70 | 865.48 | 606.85 | 4,431.83 |

| Other Comprehensive Income (Loss) | (6.73) | 1.69 | (4.61) | (5.04) | (1.57) | 4.06 |

| Total Comprehensive Income | 417.49 | 442.95 | 292.09 | 860.44 | 605.28 | 4,435.89 |

Earnings Per Share (EPS) & Capital

Paid-up equity share capital: ₹572.25 million (face value ₹10 per share) across all periods.
Basic and diluted EPS (₹): 7.41 for Q2 Sep-2026; 7.70 for Q2 Jun-2026; 5.18 for Q2 Sep-2025; 15.12 for H1 Sep-2026; 10.60 for H1 Sep-2025; 25.02 for FY Mar-2026.

Balance Sheet (Consolidated) (₹ million)

| | 30-Sep-2026 (Unaudited) | 31-Mar-2026 (Audited) |

| Total Assets | 19,940.83 | 18,378.14 |

| Total Equity | 11,675.58 | 10,815.14 |

| Total Liabilities | 8,265.25 | 7,563.00 |

Cash Flow (Consolidated) (₹ million)

| | H1 Ended 30-Sep-2026 (Unaudited) | H1 Ended 30-Sep-2025 (Unaudited) |

| Net cash from Operating Activities | 725.59 | 297.19 |

| Net cash used in Investing Activities | (644.06) | (354.74) |

| Net cash from/(used in) Financing Activities | 30.52 | (92.25) |

| Net Increase/(Decrease) in Cash | 112.05 | (149.80) |

| Cash and equivalents at period end | 148.56 | 5.39 |

Detailed Financial Performance (Standalone)

Income Statement (₹ million)

| Revenue from operations | 4,047.75 | 4,004.76 | 2,898.31 | 8,052.51 | 5,768.10 | 12,988.14 |

| Other income | 29.00 | 27.02 | 46.31 | 56.02 | 89.46 | 132.43 |

| Total Income | 4,076.75 | 4,031.78 | 2,944.62 | 8,108.53 | 5,857.56 | 13,120.57 |

| Total Expenses | 3,656.53 | 3,601.44 | 2,751.93 | 7,257.97 | 5,391.95 | 12,002.35 |

| Profit before tax | 420.22 | 430.34 | 192.69 | 850.56 | 465.61 | 1,118.22 |

| Tax expense | 100.53 | 109.74 | 49.35 | 210.27 | 119.32 | 268.91 |

| Profit for the period | 319.69 | 320.60 | 143.34 | 640.29 | 346.29 | 849.31 |

| Other Comprehensive Income (Loss) | (4.09) | (1.26) | (1.32) | (5.35) | (4.04) | (0.55) |

| Total Comprehensive Income | 315.60 | 319.34 | 142.02 | 634.94 | 342.25 | 848.76 |

Earnings Per Share (EPS) & Capital

Paid-up equity share capital: ₹572.25 million (face value ₹10 per share) across all periods.
Basic and diluted EPS (₹): 5.59 for Q2 Sep-2026; 5.60 for Q2 Jun-2026; 2.50 for Q2 Sep-2025; 11.19 for H1 Sep-2026; 6.05 for H1 Sep-2025; 14.84 for FY Mar-2026.

Balance Sheet (Standalone) (₹ million)

| | 30-Sep-2026 (Unaudited) | 31-Mar-2026 (Audited) |

| Total Assets | 16,735.75 | 15,470.85 |

| Total Equity | 9,513.87 | 8,878.93 |

| Total Liabilities | 7,221.88 | 6,591.92 |

Auditor Review

The statutory auditors of the Company, B S R & Co. LLP (Firm Registration No.: 101248W/W-100022), have issued an unmodified limited review report on both the unaudited consolidated and standalone financial results for the quarter and half year ended 30 September 2026.
The review was conducted by Partner Manish Gupta (Membership No.: 095037).
For the consolidated results, the review report notes that the interim financial information of one subsidiary (Univentis Foundation) was not reviewed by B S R & Co. LLP but was reviewed by another auditor. The figures for this subsidiary are immaterial to the Group.

Segment Information

The Group and the Company each have only one reportable segment: "Drugs and pharmaceutical products" as per Ind AS 108.
Accordingly, segment-wise disclosures as per SEBI LODR regulations are not applicable.

Entities Included in Consolidation

The consolidated results include the following entities (all incorporated in India):

1. Innova Captab Limited (Parent)

2. Univentis Medicare Limited (Wholly-Owned Subsidiary)

3. Sharon Bio-Medicine Limited (Step-Down Subsidiary)

4. Univentis Foundation (Subsidiary)

Compliance and Availability

The financial results have been prepared in accordance with Ind AS 34 and SEBI Listing Regulations.
The results were reviewed by the Audit Committee and approved by the Board of Directors on 13 November 2026.
The results are available on the Company's website (www.innovacaptab.com) and on the stock exchange websites (www.bseindia.com and www.nseindia.com).